1,269 results on '"Elisei, Rossella"'
Search Results
152. Radionuclide Therapy of Thyroid Tumors
153. Diagnostic Applications of Nuclear Medicine: Thyroid Tumors
154. Thyroidectomies in Italy: A Population-Based National Analysis from 2001 to 2018
155. Bilateral testicular metastases of MTC in an adult male with MEN2A syndrome: case report and review of literature
156. Looking for RETalterations in thyroid cancer: clinical relevance, methodology and timing
157. Bilateral testicular metastases of MTC in an adult male with MEN2A syndrome: case report and review of literature
158. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
159. Response to Letter to the Editor from Green and Gosmanov: Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management
160. Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism
161. Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center
162. Thyroidectomies in Italy: A population-based national analysis from 2001 to 2018
163. Il carcinoma tiroideo: nuove prospettive terapeutiche
164. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
165. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
166. Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico: Proposto da Paolo Vitti
167. Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia
168. Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
169. Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?
170. Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib
171. Il profilo delle mutazioni somatiche nella variante hobnail del carcinoma papillare della tiroide
172. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
173. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
174. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
175. Effects of radioiodine treatment for differentiated thyroid cancer on testis function
176. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer.
177. Carcinoma tiroideo e gravidanza: Proposto da Rossella Elisei
178. Medullary Thyroid Carcinoma in Children
179. Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma
180. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer
181. Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System
182. Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors
183. MANAGEMENT OF ENDOCRINE DISEASE: Papillary thyroid microcarcinoma: toward an active surveillance strategy
184. Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs
185. Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution
186. Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer
187. Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management
188. Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST
189. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer
190. Incidentaloma surrenalico: dalla identificazione alla scelta terapeutica
191. Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze
192. Novel Genome-Wide Association Study–Based Candidate Loci for Differentiated Thyroid Cancer Risk
193. Molecular Profiles of Papillary Thyroid Tumors Have Been Changing in the Last Decades: How Could We Explain It?
194. Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
195. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).
196. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
197. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival
198. Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
199. TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations
200. Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.